Exploratory Analysis on the Use of Statins with or without n-3 PUFA and Major Events in Patients Discharged for Acute Myocardial Infarction: An Observational Retrospective Study

PLoS ONE

Volumn 8, Issue 5, 2013, Pages

  Macchia, Alejandro ^a,b   Romero, Marilena ^a   D'Ettorre, Antonio ^a   Tognoni, Gianni ^a   Mariani, Javier ^b  

^a Laboratory of Pharmacoepidemiology   (Italy)

^b Ciudad Autónoma de Buenos Aires   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; OMEGA 3 FATTY ACID;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; COHORT ANALYSIS; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; FEMALE; FOLLOW UP; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART REINFARCTION; HUMAN; ITALY; MAJOR CLINICAL STUDY; MALE; MORTALITY; OBSERVATIONAL STUDY; RETROSPECTIVE STUDY; SURVIVAL RATE;

AGED; DRUG THERAPY, COMBINATION; FATTY ACIDS, OMEGA-3; FEMALE; HEPTANOIC ACIDS; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MATCHED-PAIR ANALYSIS; MIDDLE AGED; MYOCARDIAL INFARCTION; PYRROLES; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; SIMVASTATIN; TREATMENT OUTCOME;

EID: 84877095973     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0062772     Document Type: Article

References (29)

1. GISSI-Prevenzione Investigators (Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico) (1999) Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Lancet 354: 447-455.
2. Marchioli R, Barzi F, Bomba E, (2002) Chieffo C, Di Gregorio D, et al (2002) Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction: time-course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI)-Prevenzione. Circulation 105: 1897-1903.
3. Yokoyama M, Origasa H, Matsuzaki M, Matsuzawa Y, Saito Y, et al. (2007) Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet 369: 1090-1098.
4. Galan P, Kesse-Guyot E, Czernichow S, Briancon S, Blacher J, et al.; SU.FOL.OM3 Collaborative Group (2010) Effects of B vitamins and omega 3 fatty acids on cardiovascular diseases: a randomised placebo controlled trial. BMJ 341: c6273 doi: 10.1136/bmj.c6273.
5. Kromhout D, Giltay EJ, (2010) Geleijnse JM; Alpha Omega Trial Group (2010) n-3 fatty acids and cardiovascular events after myocardial infarction. N Engl J Med 363: 2015-2026.
6. ORIGIN Trial Investigators, Bosch J, Gerstein HC, Dagenais GR, Díaz R, Dyal L, et al. (2012) n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia. N Engl J Med 367: 309-318.
7. Kwak SM, Myung SK, Lee YJ, (2012) Seo HG; Korean Meta-analysis Study Group (2012) Efficacy of omega-3 fatty acid supplements (eicosapentaenoic acid and docosahexaenoic acid) in the secondary prevention of cardiovascular disease: a meta-analysis of randomized, double-blind, placebo-controlled trials. Arch Intern Med 172: 686-694.
8. Rauch B, Schiele R, Schneider S, Diller F, Victor N, et al. (2010) OMEGA, a randomized, placebo-controlled trial to test the effect of highly purified omega-3 fatty acids on top of modern guideline-adjusted therapy after myocardial infarction. Circulation 122: 2152-2159.
9. Davidson MH, Stein EA, Bays HE, Maki KC, Doyle RT, et al. (2007) Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled study. Clin Ther 29: 1354-1367.
10. Maki KC, McKenney JM, Reeves MS, Lubin BC, Dicklin MR, (2008) Effects of adding prescription omega-3 acid ethyl esters to simvastatin (20 mg/day) on lipids and lipoprotein particles in men and women with mixed dyslipidemia. Am J Cardiol 102: 429-433.
11. Gissi-HF Investigators, Tavazzi L, Maggioni AP, Marchioli R, Barlera S, et al. (2008) Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet 372: 1223-1230.
12. Ayanian JZ, (1999) Using administrative data to assess health care outcomes. Eur Heart J 20: 1689-1691.
13. Monte S, Macchia A, Pellegrini F, Romero M, Lepore V, et al. (2006) Antithrombotic treatment is strongly underused despite reducing overall mortality among high-risk elderly patients hospitalized with atrial fibrillation. Eur Heart J 27: 2217-2223.
14. WHO Collaborating Centre for Drug Statistics Methodology (2003) ATC Index with DDDs. Oslo, Norway: WHO.
15. Kalbfleisch JD, Prentice RL (1980) The Statistical Analysis of Failure Time Data. New York: John Wiley.
16. Therneau TM, Grambsch PM (2000) Modeling Survival Data: Extending the Cox Model. New York: Springer.
17. Collett D (1994) Modelling Survival Data in Medical Research. London: Chapman and Hall.
18. Cox DR, (1972) Regression models and life-tables. Journal of the Royal Statistical Society B 34: 187-220.
19. Mozaffarian D, Rimm EB, (2006) Fish intake, contaminants, and human health: evaluating the risks and the benefits. JAMA 296: 1885-1899.
20. León H, Shibata MC, Sivakumaran S, Dorgan M, Chatterley T, et al. (2008) Effect of fish oil on arrhythmias and mortality: systematic review. BMJ 337: a2931 doi: 10.1136/bmj.a2931.
21. Yamagishi K, Iso H, Date C, Fukui M, Wakai K, et al. (2008) Fish, omega-3 polyunsaturated fatty acids, and mortality from cardiovascular diseases in a nationwide community-based cohort of Japanese men and women the JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk) Study. J Am Coll Cardiol 52: 988-996.
22. Kromhout D, Geleijnse JM, de Goede J, Oude Griep LM, Mulder BJ, et al. (2011) n-3 fatty acids, ventricular arrhythmia-related events, and fatal myocardial infarction in postmyocardial infarction patients with diabetes. Diabetes Care 34: 2515-2520.
23. Leaf A, Albert CM, Josephson M, Steinhaus D, Kluger J, et al. (2005) Prevention of fatal arrhythmias in high-risk subjects by fish oil n-3 fatty acid intake. Circulation 112: 2762-2768.
24. Harris WS, Mozaffarian D, Lefevre M, Toner CD, Colombo J, et al. (2009) Towards establishing dietary reference intakes for eicosapentaenoic and docosahexaenoic acids. J Nutr 139: 804S-819S.
25. Duda MK, O'Shea KM, Tintinu A, Xu W, Khairallah RJ, et al. (2009) Fish oil, but not flaxseed oil, decreases inflammation and prevents pressure overload-induced cardiac dysfunction. Cardiovasc Res 81: 319-327.
26. Teng LL, Shao L, Zhao YT, Yu X, Zhang DF, et al. (2010) The beneficial effect of n-3 polyunsaturated fatty acids on doxorubicin-induced chronic heart failure in rats. J Int Med Res 38: 940-948.
27. Byar DP, (1991) Problems with using observational databases to compare treatments. Stat Med 10: 663-666.
28. Austin PC, Mamdani MM, Stukel TA, Anderson GM, Tu JV, (2005) The use of the propensity score for estimating treatment effects: administrative versus clinical data. Stat Med 24: 1563-1578.
29. Biondi-Zoccai G, Romagnoli E, Agostoni P, Capodanno D, Castagno D, et al. (2011) Are propensity scores really superior to standard multivariable analysis? Contemp Clin Trials 32: 731-740 doi: 10.1016/j.cct.2011.05.006.